We report the first successful treatment with the IL-1 receptor antagonist anakinra, in
association with the most promising and available antiviral therapy, of a severe case of …

Despite the progressing knowledge in COVID-19 management, remdesivir is the only agent
that got approval to inhibit viral replication. However, there are limited data about effective …

Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant
inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a …

The IL-1 receptor antagonist, anakinra, may represent a therapeutic option for acute
respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID …

Background Coronaviruses can induce the production of interleukin (IL)-1β, IL-6, tumour
necrosis factor, and other cytokines implicated in autoinflammatory disorders. It has been …

Introduction Little evidence appears to exist for the use of anakinra, a recombinant
interleukin-1 receptor antagonist, after non-response to treatment with corticosteroids alone …

Introduction The European Medicines Agency (EMA) and the United States Food and Drug
Administration (FDA) announced conditions for using recombinant human interleukin-1 …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently discovered
coronavirus, is responsible for COVID-19, a newly emerged disease that has become …

Background Mortality of patients with coronavirus disease 2019 (COVID-19), acute
respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of …

Background: Immunomodulatory drugs have been used in patients with severe COVID-19.
The objective of this study was to evaluate the effects of two different strategies, based either …